The company's lead program, motixafortide, has shown promising results in Phase 3 and Phase 2a studies for stem cell mobilization in bone-marrow transplantation and the treatment of pancreatic cancer, respectively. Motixafortide is also being evaluated in investigator-initiated trials for pancreatic cancer in combination with other treatments, as well as for patients with Acute Respiratory Distress Syndrome (ARDS) Secondary to COVID-19 and other respiratory viral infections. BioLineRx is also developing AGI-134, a novel immunotherapy treatment for multiple solid tumors, currently in Phase 1/2a study. The company's business model involves in-licensing novel compounds, advancing them through clinical stages, and partnering with pharmaceutical companies for further development and commercialization.